Alan Musso serves as the Chief Financial Officer at Fulcrum Therapeutics Inc., a biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases. With a robust background in finance and biotechnology, Musso brings a wealth of experience to his role at Fulcrum. He joined the company in 2018 and has been instrumental in steering its financial strategy and growth. Prior to Fulcrum, Musso held the position of CFO at Tokai Pharmaceuticals, where he played a key role in managing the company's financial operations and leading it through an IPO. Musso's career spans over two decades, during which he has held various leadership positions in the life sciences industry. Before his tenure at Tokai, he was the Vice President of Finance at Human Genome Sciences, where he managed financial planning and analysis, contributing significantly to the company's growth and eventual acquisition by GlaxoSmithKline. His expertise in financial management, strategic planning, and investor relations has been pivotal in navigating Fulcrum through its various stages of development, including advancing its clinical programs and securing funding for its innovative therapies. At Fulcrum Therapeutics, Musso's primary responsibilities include overseeing the company's financial operations, which encompass budgeting, forecasting, and financial reporting. His strategic vision has been crucial in guiding Fulcrum's investment decisions and ensuring the company's fiscal health as it progresses towards bringing new treatments to market. Under his leadership, Fulcrum has successfully raised significant capital through public and private financings, enabling the company to advance its pipeline and expand its research efforts. Musso's commitment to financial excellence and his deep understanding of the biotech sector continue to drive Fulcrum's mission to develop transformative therapies for patients with rare diseases.